51 min listen
CRISPR-Cas9 for TTR Amyloidosis; Osmotic Demyelination Syndrome
CRISPR-Cas9 for TTR Amyloidosis; Osmotic Demyelination Syndrome
ratings:
Length:
22 minutes
Released:
Oct 11, 2021
Format:
Podcast episode
Description
In the first part of the podcast, Dr. Alberto Espay talks with Prof. Julian Gillmore about CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. In the second segment, Dr. Pearce Korb discusses the long-term outcomes of osmotic demyelination syndrome in an updated cohort with Dr. Whitney Fitts.
Released:
Oct 11, 2021
Format:
Podcast episode
Titles in the series (100)
October 16 2007 Issue: Disease-modifying therapies for Alzheimer disease: Challenges to early intervention by Neurology® Podcast